Seminars in Oncology
Volume 29, Issue 4 , Pages 341-352 , August 2002

The role of sentinel lymph node biopsy for melanoma

References 

  1. Greenlee RT, Hill-Harmon MB, Murray T, et al.  Cancer statistics, 2001. CA Cancer J Clin. 1999;49:8–31
  2. Rigel DS, Kopf AW, Friedman RJ. The rate of malignant melanoma in the United States: Are we making an impact?. J Am Acad Dermatol. 1987;17:1050–1053
  3. Morton DL, Davtyan DG, Wanek LA, et al.  Multivariate analysis of the relationsip between survival and the microstage of primary melanoma by Clark level and Breslow thickness. Cancer. 1993;71:3737–3743
  4. Coit DG, Rogatko A, Brennan MF. Prognostic factors in patients with melanoma metastatic to axillary or inguinal lymph nodes. A multivariate analysis. Ann Surg. 1991;214:627–636
  5. Balch CM, Soong SJ, Shaw HM, et al.  An analysis of prognostic factors in 8500 patients with cutaneous melanoma. In: ed 2.  Balch CM,  Houghton AN,  Milton GW, et al. editor. Cutaneous Melanoma. Philadelphia, PA: Lippincott; 1992;p. 165–187
  6. Morton DL, Wanek L, Nizze JA, et al.  Improved long-term survival after lymphadenectomy of melanoma metastatic to regional nodes. Analysis of prognostic factors in 1134 patients from John Wayne Cancer Clinic. Ann Surg. 1991;214:491–499
  7. Hochwald SN, Coit DG. Role of elective lymph node dissection in melanoma. Semin Surg Oncol. 1998;14:276–282
  8. Drepper H, Kohler C, Bastian B, et al.  Benefit of elective lymph node dissection in subgroups of melanoma patients. Cancer. 1993;72:741–749
  9. Reintgen D, Cox E, McCarty KJ, et al.  Efficacy of elective lymph node dissection in patients with intermediate-thickness primary melanoma. Ann Surg. 1983;198:379–385
  10. Slingluff CL, Stidham KR, Ricci WM, et al.  Surgical management of regional lymph nodes in patients with melanoma: Experience with 4682 patients. Ann Surg. 1994;219:120–130
  11. Coates AS, Ingvar CI, Petersen-Schaefer K, et al.  Elective lymph node dissection in patients with primary melanoma of the trunk and limbs treated at the Sydney melanoma unit from 1960 to 1991. J Am Coll Surg. 1995;180:402–409
  12. Ross MI. The case for elective lymphadenectomy. Surg Oncol Clin North Am. 1992;1:205–222
  13. Sims FH, Taylor WF, Pritchard DJ, et al.  Lymphadenectomy in the management of stage I malignant melanoma: A prospective randomized study. Mayo Clin Proc. 1986;61:697–705
  14. Pritchard DJ, Sims FH. Surgical management of malignant melanoma of the trunk and extremities. Mayo Clin Proc. 1989;64:846–851
  15. Sims FJ, Nelson TI, Pritchard DJ. Malignant melanoma: Mayo Clinic experience. Mayo Clin Proc. 1997;72:565–569
  16. Veronesi U, Adamus J, Bandiera DC, et al.  Delayed regional lymph node dissection in stage I melanoma of the skin of the lower extremities. Cancer. 1982;49:2420–2430
  17. Cascinelli N, Morabito A, Santinami M, et al.  Immediate or delayed dissection of regional nodes in patients with melanoma of the trunk: A randomized trial. WHO Melanoma Programme. Lancet. 1998;351:793–796
  18. Crowley NJ. The case against elective lymphadenectomy. Surg Oncol Clin North Am. 1992;1:223–246
  19. Urist MM, Maddox WA, Kennedy JE, et al.  Patient risk factors and surgical morbidity after regional lymphadenectomy in 204 melanoma patients. Cancer. 1983;51:2152–2156
  20. Morton DL, Chan AD. Current status of intraoperative lymphatic mapping and sentinel lymphadenectomy for melanoma: is it standard of care?. J Am Coll Surg. 1999;189:214–223
  21. Morton DL, Wen DR, Wong JH, et al.  Technical details of intraoperative lymphatic mapping for early-stage melanoma. Arch Surg. 1992;127:392–399
  22. Reintgen D, Cruse CW, Wells K, et al.  The orderly progression of melanoma nodal metastases. Ann Surg. 1994;220:759–767
  23. Thompson JF, McCarthy WH, Bosch CM, et al.  Sentinel lymph node status as an indicator of the presence of metastatic melanoma in regional lymph nodes. Melanoma Res. 1995;5:255–260
  24. Morton DL, Thompson JF, Essner R, et al.  Validation of the accuracy of intraoperative lymphatic mapping and sentinel lymphadenectomy for early-stage melanoma—A multicenter trial. Ann Surg. 1999;4:453–465
  25. Essner R, Bostick PJ, Glass EC, et al.  Standardized probe-directed sentinel node dissection in melanoma. Surgery. 2000;127:26–31
  26. Tanabe KK, Reintgen D. The role of sentinel lymph node mapping for melanoma. Adv Surg. 1998;31:79–103
  27. Buzaid AC, Tinoco LA, Jendiroba D, et al.  Prognostic value of size of lymph node metastases in patients with cutaneous melanoma. J Clin Oncol. 1995;13:2361–2368
  28. Balch CM, Buzaid AC, Atkins MB, et al.  A new AJCC staging system for cutaneous melanoma. Cancer. 2000;88:1484–1491
  29. Wong JH. A historical perspective on the development of intraoperative lymphatic mapping and selective lymphadenectomy. Surg Clin North Am. 2000;80:1675–1682
  30. Balch CM, Milton GW, Cascinelli N, et al.  Elective lymph node dissection: Pros and cons. In: ed 2.  Balch CM,  Houghton AN,  Milton GW, et al. editor. Cutaneous Melanoma. Philadelphia, PA: Lippincott; 1992;p. 345–366
  31. Ross MI. Role of lymphatic mapping and sentinel node biopsy in melanoma detection. Eur J Cancer. 1998;34(suppl):S7–S11
  32. Balch CM, Soong SJ, Bartolucci AA, et al.  Efficacy of an elective regional lymph node dissection of 1 to 4 mm thick melanomas for patients 60 years of age and younger. Ann Surg. 1996;224:255–266
  33. Cabanas RM. An approach for the treatment of penile carcinoma. Cancer. 1977;39:456–466
  34. Leong SP. The role of sentinel lymph nodes in malignant melanoma. Surg Clin North Am. 2000;80:1741–1757
  35. Wong JH, Cagle LA, Morton DL. Lymphatic drainage of skin to a sentinel lymph node in a feline model. Ann Surg. 1991;214:637–641
  36. Alex JC, Weaver DL, Fairbank JT, et al.  Gamma-probe-guided lymph node localization in malignant melanoma. Surg Oncol. 1993;2:303–308
  37. Albertini JJ, Cruse CW, Rapaport D, et al.  Intraoperative radiolymphoscintigraphy improves sentinel lymph node identification for patients with melanoma. Ann Surg. 1996;223:217–224
  38. Krag DN, Meijer SJ, Weaver DL, et al.  Minimal-access surgery for staging of malignant melanoma. Arch Surg. 1995;130:654–658
  39. Leong SP, Donegan E, Heffernon W, et al.  Adverse reactions to isosulfan blue during selective sentinel lymph node dissection in melanoma. Ann Surg Oncol. 2000;7:361–366
  40. Wallace A, Hoh C, Vera D. A new radiopharmaceutical for sentinel node detection: 99mTcDTPA A-mannosyl-dextran. In: Sentinel Node 2000, Santa Monica, CA. December 1-4, 2000;p. 1–4 (abstr)
  41. Reintgen D, Rapaport D, Tanabe KK, et al.  Lymphatic mapping and sentinel lymphadenectomy. In: ed 3.  Balch CM,  Houghton AM,  Sober AJ, et al. editor. Cutaneous Melanoma. St Louis, MO: Quality Medical Publishing; 1998;p. 227–244
  42. Leong SP, Steinmetz I, Habib FA, et al.  Optimal selective sentinel lymph node dissection in primary malignant melanoma. Arch Surg. 1997;132:666–673
  43. Lingham MK, Mackie RM, McKay AJ. Intraoperative identification of sentinel lymph node in patients with malignant melanoma. Br J Cancer. 1997;75:1505–1508
  44. Jansen L, Nieweg OE, Peterse JL, et al.  Reliability of sentinel lymph node biopsy for staging melanoma. Br J Surg. 2000;87:484–489
  45. Nieweg OE, Tanis PJ, Rutgers EJ. Summary of the second international sentinel node conference. Eur J Nucl Med. 2001;28:646–649
  46. Cascinelli N. WHO melanoma programme: Results of sentinel node study. In: Sentinel Node 2000, Santa Monica, CA. December 1-4, 2000;p. 1–4 (abstr)
  47. Kelley MC, Ollila DW, Morton DL. Lymphatic mapping and sentinel lymphadenectomy for melanoma. Semin Surg Oncol. 1998;14:283–290
  48. Norman J, Cruse CW, Wells K, et al.  A redefinition of skin lymphatic drainage by lymphoscintigraphy for malignant melanoma. Am J Surg. 1991;162:432–437
  49. Leong SP, Habib FA, Achtem TA, et al.  Discordancy between clinical predictions versus lymphoscintigraphic and intraoperative mapping of sentinel lymph node drainage of primary melanoma. Arch Dermatol. 1999;135:1472–1476
  50. Uren DF, Howman-Giles RB, Shaw HM, et al.  Lymphoscintigraphy in high risk melanoma of the trunk: Predicting draining node groups, defining lymphatic channels and locating the sentinel node. J Nucl Med. 1993;34:1435–1440
  51. Cochran AJ. Melanoma metastases through the lymphatic system. Surg Clin North Am. 2000;80:1683–1693
  52. Morton DL. Introduction: Sentinel lymphadenectomy for patients with clinical stage I melanoma. J Surg Oncol. 1997;66:267–269
  53. Essner R. The role of lymphoscintigraphy and sentinel node mapping in assessing patient risk in melanoma. Semin Oncol. 1997;24(suppl):S4–S8
  54. Kelemen PR, Essner R, Foshag LJ, et al.  Lymphatic mapping and sentinel lymphadenectomy after wide local excision of primary melanoma. J Am Coll Surg. 1999;189:247–252
  55. Cochran AJ, Balda BR, Starz H, et al.  The Augsburg Consensus—Techniques of lymphatic mapping, sentinel lymphadenectomy, and completion lymphadenectomy in cutaneous malignancies. Cancer. 2000;89:236–241
  56. Gershenwald JE, Colome MI, Lee JE, et al.  Patterns of recurrence following a negative sentinel lymph node biopsy in 243 patients with stage I or II melanoma. J Clin Oncol. 1998;16:2253–2260
  57. Heller R, Becker J, Wassalle J, et al.  Detection of submicroscopic lymph node mestastases in patients with malignant melanoma. Arch Surg. 1991;126:1455–1460
  58. Wang X, Heller R, Voorheis N, et al.  Detection of submicroscopic lymph node metastases with polymerase chain reaction in patients with malignant melanoma. Ann Surg. 1994;220:768–774
  59. Gogel BM, Kuhn JA, Ferry KM, et al.  Sentinel lymph node biopsy for melanoma. Am J Surg. 1998;176:544–547
  60. Gershenwald JE, Thompson W, Mansfield PF, et al.  Multi-institutional melanoma lymphatic mapping experience: Prognostic value of sentinel lymph node status in 612 stage I or II melanoma patients. J Clin Oncol. 1999;17:973–983
  61. Clary BM, Brady MS, Lewis JJ, et al.  Sentinel lymph node biopsy in the management of patients with primary cutaneous melanoma: Review of a large single-institutional experience with an emphasis on recurrence. Ann Surg. 2001;233:250–258
  62. Gadd MA, Cosimi B, Yu J, et al.  Outcome of patients with melanoma and histologically negative sentinel lymph nodes. Arch Surg. 1999;134:381–387
  63. Gershenwald JE, Mansfield PF, Lee JE, et al.  Role for lymphatic mapping and sentinel lymph node biopsy in patients with thick (>4 mm) primary melanoma. Ann Surg Oncol. 2000;7:160–165
  64. Kirkwood JM, Strawderman MH, Ernstoff MS, et al.  Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: The Eastern Cooperative Oncology Groups trial EST 1684. J Clin Oncol. 1996;14:7–17

☆ Address reprint requests to Michael Bouvet, MD, University of California San Diego, Department of Surgery, 3350 La Jolla Village Dr (112E), San Diego, CA 92161.

PII: S0093-7754(02)50264-5

doi: 10.1053/sonc.2002.34112

Seminars in Oncology
Volume 29, Issue 4 , Pages 341-352 , August 2002

Article Tools

* Image Usage & Resolution